Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)
Year: 2013
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Washington University in St. Louis, Duke Medical Center, The Ohio State University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Wake Forest University, University of Maryland, Baltimore, University of Chicago, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W103524613